• ATRiBRAVE trial written informed consent, prior to any study specific procedures

• Age ≥18 years old

• Ability to comply with the study protocol in the investigator's judgment.

• Ability to swallow and retain oral medication

• Availability of a formalin-fixed, paraffin-embedded block (FFPE) containing primary tumor tissue or at least 10-20 unstained tumor slides

• Metastatic TNBC patients who have not received prior systemic cytotoxic therapy in the advanced setting and whose tumor have relapsed from treatment with curative intent for early disease, which must have included ICI and chemotherapy as part of radical locoregional therapy

• Documented disease progression (e.g., with biopsy sample, pathology or imaging report) since the last treatment in the early setting with curative intent (neo/adjuvant regimen)

• Negative ER/PgR (defined as \<10% of tumor cells expressing ER and PgR hormonal receptors) and HER2 status (HER2 IHC score 0, 1+ or 2+ non-amplified by in situ hybridization) must be confirmed in the most recent tumor sample (primary and/or metastatic)

• Evaluable disease, as defined by RECIST 1.1

⁃ ECOG performance status 0-1 (refer to Appendix 1)

⁃ Patients must have a life expectancy ≥ 3 months from proposed first dose date.

⁃ Patients must have acceptable bone marrow, liver and renal functions measured within 28 days prior to administration of study treatment

⁃ Body weight \> 30kg

⁃ Women with childbearing potential should complete a pregnancy test with negative result within 28 days of study treatment and be willing to use effective contraceptive methods from screening to 90 days after the last dose of durvalumab

⁃ For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm from screening to 90 days after the last dose of durvalumab.